Department of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt.
Department of Biochemistry, Sphinx University, New Assiut City, Assiut 10, Egypt.
Mol Biol Rep. 2024 Jan 6;51(1):79. doi: 10.1007/s11033-023-09009-9.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 caused a pandemic of acute respiratory disease, named coronavirus disease 2019 (COVID-19). COVID-19 became one of the most challenging health emergencies, hence the necessity to find different prognostic factors for disease progression, and severity. Membrane bound O-acyltransferase domain containing 7 (MBOAT7) demonstrates anti-inflammatory effects through acting as a fine-tune regulator of the amount of cellular free arachidonic acid. We aimed in this study to evaluate MBOAT7 expression in COVID-19 patients and to correlate it with disease severity and outcomes.
This case-control study included 56 patients with confirmed SARS-CoV-2 diagnosis and 28 control subjects. Patients were further classified into moderate (n = 28) and severe (n = 28) cases. MBOAT7, tumor necrosis factor-α (TNF-α), and interleukin-1ß (IL-1ß) mRNA levels were evaluated in peripheral blood mononuclear cells (PBMC) samples isolated from patients and control subjects by real time quantitative polymerase chain reaction (RT-qPCR). In addition, circulating MBOAT7 protein levels were assayed by enzyme-linked immunosorbent assay (ELISA).
Significant lower levels of circulating MBOAT7 mRNA and protein were observed in COVID-19 patients compared to control subjects with severe COVID-19 cases showing significant lower levels compared to moderate cases. Moreover, severe cases showed a significant upregulation of TNF-α and IL-1ß mRNA. MBOAT7 mRNA and protein levels were significantly correlated with inflammatory markers (TNF-α, IL-1ß, C-reactive protein (CRP), and ferritin), liver enzymes, severity, and oxygen saturation levels.
COVID-19 is associated with downregulation of MBAOT7, which correlates with disease severity.
2019 年末严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的出现引发了急性呼吸道疾病大流行，被命名为 2019 年冠状病毒病（COVID-19）。COVID-19 成为最具挑战性的卫生突发事件之一，因此有必要寻找不同的疾病进展和严重程度的预后因素。膜结合酰基转移酶结构域包含 7（MBOAT7）通过作为细胞游离花生四烯酸量的精细调节因子发挥抗炎作用。我们旨在本研究中评估 COVID-19 患者中 MBOAT7 的表达，并将其与疾病严重程度和结局相关联。
这项病例对照研究纳入了 56 例确诊为 SARS-CoV-2 感染的患者和 28 名对照者。患者进一步分为中度（n=28）和重度（n=28）病例。通过实时定量聚合酶链反应（RT-qPCR）评估分离自患者和对照者外周血单个核细胞（PBMC）样本中 MBOAT7、肿瘤坏死因子-α（TNF-α）和白细胞介素-1β（IL-1β）的 mRNA 水平。此外，通过酶联免疫吸附试验（ELISA）测定循环 MBOAT7 蛋白水平。
与对照组相比，COVID-19 患者的循环 MBOAT7 mRNA 和蛋白水平显著降低，重度 COVID-19 患者的水平明显低于中度病例。此外，重度病例的 TNF-α和 IL-1β mRNA 表达显著上调。MBOAT7 mRNA 和蛋白水平与炎症标志物（TNF-α、IL-1β、C 反应蛋白（CRP）和铁蛋白）、肝酶、严重程度和氧饱和度水平显著相关。
COVID-19 与 MBOAT7 的下调相关，MBOAT7 与疾病严重程度相关。
